- Home
- CVKD vs MIRA Comparison
CVKD vs MIRA Comparison
Compare CVKD & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- MIRA
- Stock Information
- Founded
- CVKD 2022
- MIRA 2020
- Country
- CVKD United States
- MIRA United States
- Employees
- CVKD N/A
- MIRA N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- MIRA Health Care
- Exchange
- CVKD Nasdaq
- MIRA Nasdaq
- Market Cap
- CVKD 17.1M
- MIRA 17.1M
- IPO Year
- CVKD 2023
- MIRA 2023
- Fundamental
- Price
- CVKD $15.24
- MIRA $1.05
- Analyst Decision
- CVKD Strong Buy
- MIRA Strong Buy
- Analyst Count
- CVKD 2
- MIRA 2
- Target Price
- CVKD $52.50
- MIRA $14.00
- AVG Volume (30 Days)
- CVKD 59.6K
- MIRA 538.5K
- Earning Date
- CVKD 11-08-2024
- MIRA 11-11-2024
- Dividend Yield
- CVKD N/A
- MIRA N/A
- EPS Growth
- CVKD N/A
- MIRA N/A
- EPS
- CVKD N/A
- MIRA N/A
- Revenue
- CVKD N/A
- MIRA N/A
- Revenue This Year
- CVKD N/A
- MIRA N/A
- Revenue Next Year
- CVKD N/A
- MIRA N/A
- P/E Ratio
- CVKD N/A
- MIRA N/A
- Revenue Growth
- CVKD N/A
- MIRA N/A
- 52 Week Low
- CVKD $5.40
- MIRA $0.51
- 52 Week High
- CVKD $32.55
- MIRA $6.40
- Technical
- Relative Strength Index (RSI)
- CVKD 60.90
- MIRA 38.49
- Support Level
- CVKD $11.19
- MIRA $1.05
- Resistance Level
- CVKD $15.93
- MIRA $1.12
- Average True Range (ATR)
- CVKD 1.36
- MIRA 0.07
- MACD
- CVKD 0.23
- MIRA 0.02
- Stochastic Oscillator
- CVKD 61.01
- MIRA 12.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.